AS-S603 / Amyloid Solution - LARVOL DELTA

Vascular Contributions to Cognitive Impairment and Dementia in the United States: Prevalence and Incidence: A Scientific Statement From the American Heart Association. (PubMed, Stroke) - "In 2020, as many as 603 000 new individuals developed new vascular dementia or mixed vascular dementia according to epidemiological studies, whereas there were 102 000 new cases according to health care billing data...Indeed, we estimate that eliminating cerebrovascular disease from the population would prevent 27% to 33% of dementia cases, resulting in 1.5 to 1.8 million fewer people with dementia in 2020. Population health approaches to reduce VCID would benefit millions of Americans."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Vascular Neurology

Korean biopharma firms to unveil new Alzheimer's drugs at AAIC 2025 (Korea Biomedical Review) - "Amyloid Solution will present the preclinical study results of 'AS-S603' orally on Tuesday and present the diagnostic device in a poster presentation....In preclinical trials, it demonstrated superior cognitive improvement and amyloid removal effects compared to lecanemab and ALZ-001. Amyloid Solution stated that AS-S603 is a first-in-class substance that simultaneously targets Aβ and tau, the core pathologies of Alzheimer's disease, and is being developed with the expectation that it may slow the progression of the disease itself."

Preclinical • Alzheimer's Disease

A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Amyloid Solution Inc | Not yet recruiting ➔ Recruiting

Enrollment open